Cargando…

Therapeutic use of Aldara™ in chronic myeloid leukemia

The potent clinical responses seen in patients with chronic myeloid leukemia (CML) after administration of donor-specific lymphocytes, as well as the correlation between the presence of antigen specific T cells and prolonged remission in these patients, suggests a role for the immunological control...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marleau, Annette M, Lipton, Jeffrey H, Riordan, Neil H, Ichim, Thomas E
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1790884/ https://www.ncbi.nlm.nih.gov/pubmed/17254347 http://dx.doi.org/10.1186/1479-5876-5-4

Ejemplares similares

Imiquimod (Aldara cream).
por: Buck, H W
Publicado: (1998)

Cord blood in regenerative medicine: do we need immune suppression?
por: Riordan, Neil H, et al.
Publicado: (2007)

Methodological refinement of Aldara-induced psoriasiform dermatitis model in mice
por: Horváth, Szabina, et al.
Publicado: (2019)

JNK1 Signaling Downstream of the EGFR Pathway Contributes to Aldara(®)-Induced Skin Inflammation
por: Le, Aurore, et al.
Publicado: (2021)

Treatment of Verrucous Carcinoma of the Lower Lip with Topical Imiquimod (Aldara®) and Debulking Therapy
por: Kwon, Hyok Bu, et al.
Publicado: (2011)

Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?
por: Avcilar, Huseyin, et al.
Publicado: (2020)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

Management of chronic myeloid leukemia in 2023 – common ground and common sense
por: Senapati, Jayastu, et al.
Publicado: (2023)

Allogeneic endometrial regenerative cells: An "Off the shelf solution" for critical limb ischemia?
por: Murphy, Michael P, et al.
Publicado: (2008)

The Systemic Response to Topical Aldara Treatment is Mediated Through Direct TLR7 Stimulation as Imiquimod Enters the Circulation
por: Nerurkar, Louis, et al.
Publicado: (2017)

Imatinib-induced gastric antral vascular ectasia in a patient with chronic myeloid leukemia
por: Alshehry, Nawal F, et al.
Publicado: (2014)

Exosome removal as a therapeutic adjuvant in cancer
por: Marleau, Annette M, et al.
Publicado: (2012)

Chronic myeloid leukemia stem cells: targeting therapeutic implications
por: Mojtahedi, Hanieh, et al.
Publicado: (2021)

The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia
por: Wu, Andrew, et al.
Publicado: (2023)

Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
por: Aghel, Nazanin, et al.
Publicado: (2017)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec(®), Gleevec™)
por: Henkes, Martin, et al.
Publicado: (2008)

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
por: Hochhaus, A., et al.
Publicado: (2020)

B-Lymphoid Blast Phase–Chronic Myeloid Leukemia: Current Therapeutics
por: Yohannan, Binoy, et al.
Publicado: (2022)

Inclusion body myositis in a patient with chronic myeloid leukemia treated with dasatinib: a case report
por: AlJohani, Naif I., et al.
Publicado: (2015)

Bosutinib for Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2015)

RhoA: A therapeutic target for chronic myeloid leukemia
por: Molli, Poonam R, et al.
Publicado: (2012)

Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia
por: Laneuville, P., et al.
Publicado: (2006)

Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells
por: Hamad, Ahmad, et al.
Publicado: (2013)

Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate
por: Akard, Luke, et al.
Publicado: (2015)

Anti-angiogenic effect of high doses of ascorbic acid
por: Mikirova, Nina A, et al.
Publicado: (2008)

The King is Dead, Long Live the King: Entering A New Era of Stem Cell Research and Clinical Development
por: Ichim, Thomas, et al.
Publicado: (2011)

Bosutinib in chronic myeloid leukemia: patient selection and perspectives
por: Isfort, Susanne, et al.
Publicado: (2018)

Chronic Myeloid Leukemia in India
por: Ganesan, Prasanth, et al.
Publicado: (2016)

Chronic Myeloid Leukemia in 2020
por: Hehlmann, Rüdiger
Publicado: (2020)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

Leukemia stem cells: the root of chronic myeloid leukemia
por: Zhou, Hong, et al.
Publicado: (2015)

Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia
por: Li, Bing, et al.
Publicado: (2014)

Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia
por: Gurnari, Carmelo, et al.
Publicado: (2020)

Acute Myeloid Leukemia Mutations: Therapeutic Implications
por: Papayannidis, Cristina, et al.
Publicado: (2019)

Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase
por: Yohanan, Binoy, et al.
Publicado: (2022)

P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia
por: Cang, Shundong, et al.
Publicado: (2008)

Acute Myeloid Leukemia: Focus on Novel Therapeutic Strategies
por: Lin, Tara L., et al.
Publicado: (2012)

Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia
por: Price, Kimberly E, et al.
Publicado: (2013)

Stem Cell Therapy for Autism
por: Ichim, Thomas E, et al.
Publicado: (2007)

Dasatinib in chronic myeloid leukemia: a review
por: Aguilera, Dolly G, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_rgmpdu23fp49ss34494p015udh